Method development for the quantification of lead levels in whole blood sampled on Mitra<sup>®</sup> with VAMS<sup>®</sup> tips by inductively coupled plasma-MS/MS
Breton et al.
The finding, in our words
A VAMS method using Mitra devices for whole blood lead quantification showed no significant difference compared with the centre's routine method, supporting VAMS as a practical alternative for blood lead and other trace element analyses.
A paraphrase to the Library’s standard, never the abstract. The source is one link away and is always the authority.
This study validated a method for measuring the alcohol biomarker phosphatidylethanol using two volumetric absorptive microsampling devices, finding that the Mitra device met all validation criteria and agreed with venous sampling. The Capitainer device was deemed suitable but showed reduced accuracy at higher concentrations, with a small proportional negative bias compared to venous results.
In whole blood spiked with 90 drugs, the VAMS method using the Neoteryx Mitra device confirmed 87 compounds with identification limits below 12.5 ng/mL for 82.2% of drugs and extraction yields of 80.6 to 108.7%. In 15 poisoned patients, 98% of plasma compounds were detected in VAMS with satisfactory concordance (R2 = 0.827), supporting its use for decentralised toxicology screening.
Capillary VAMS combined with direct mercury analysis demonstrated strong correlation with venous blood mercury concentrations in adult volunteers, with acceptable accuracy and precision above 1.0 µg/l. Storage in pre-cleaned glass vials following two hours of desiccator drying maintained analyte stability for at least four weeks.
Researchers successfully validated an analytical method for measuring creatinine across plasma and volumetric absorptive microsampling devices, demonstrating strong correlation between conventional plasma and dried microsamples. This provides a reliable, patient-centric approach for monitoring kidney function remotely during transplant follow-up.
In lung and renal transplant recipients, VAMS sampling with LC-MS/MS quantification of mycophenolic acid and tacrolimus showed good linearity and accuracy, and with a haematocrit-adjusted conversion formula achieved clinical agreement in most samples; tacrolimus did not require haematocrit correction. The approach is virtually painless and enables richer sampling for more accurate drug exposure estimates, supporting decentralised therapeutic drug monitoring.